CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company…
Pacvue Launches Pacvue Prism, Powering the Industry’s First Agentic Commerce Grid
Shangri-La Group Debuts ‘Dragonbeat’ with Resounding Success, Cross-Industry Collaborations with Local Creators in Art, Fashion, Gastronomy and Music
EE Power Asia 2026 to Spotlight Technologies Driving the Next Era of Electrification